Dyba T, Randi G, Martos C, Giusti F, Calvalho R, Neamtiu L, Nicholson N, Flego M, Dimitrova N, Bettio M. 1501O Long-term estimates of cancer incidence and mortality for the EU and EFTA countries according to different demographic scenarios. Ann Oncol. 2021;32:S1102.

Article  Google Scholar 

Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4:e214708–e214708.

Article  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Smithy JW, O’Reilly EM. Pancreas cancer: therapeutic trials in metastatic disease. J Surg Oncol. 2021;123:1475–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dardare J, Witz A, Merlin J-L, Bochnakian A, Toussaint P, Gilson P, Harlé A. Epithelial to mesenchymal transition in patients with pancreatic ductal adenocarcinoma: State-of-the-art and therapeutic opportunities. Pharmaceuticals. 2021;14:740.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dangi-Garimella S, Krantz SB, Shields MA, Grippo PJ, Munshi HG. Epithelial-mesenchymal transition and pancreatic cancer progression. 2012.

Google Scholar 

Mahajan K, Mahajan NP. Cross talk of tyrosine kinases with the DNA damage signaling pathways. Nucleic Acids Res. 2015;43:10588–601.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discovery. 2018;17:353–77.

Article  CAS  PubMed  Google Scholar 

Mullard A. Phosphatases start shedding their stigma of undruggability. Nat Rev Drug Discovery. 2018;17:847–50.

Article  CAS  PubMed  Google Scholar 

Brautigan DL, Farrington C, Narla G. Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents. Clin Sci. 2021;135:1545–56.

Article  CAS  Google Scholar 

Dzulko M, Pons M, Henke A, Schneider G, Krämer OH. The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation. Biochim Biophys Acta Rev Cancer. 2020;1874:188453.

Article  CAS  PubMed  Google Scholar 

Haanen TJ, O’Connor CM, Narla G. Biased holoenzyme assembly of protein phosphatase 2A (PP2A): from cancer to small molecules. J Biol Chem. 2022;298:102656.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ronk H, Rosenblum JS, Kung T, Zhuang Z. Targeting PP2A for cancer therapeutic modulation. Cancer Biol Med. 2022;19:1428–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019;366:818–22.

Article  CAS  PubMed  Google Scholar 

Park J, Cho J, Song EJ. Ubiquitin–proteasome system (UPS) as a target for anticancer treatment. Arch Pharmacal Res. 2020;43:1144–61.

Article  CAS  Google Scholar 

Vargas JNS, Hamasaki M, Kawabata T, Youle RJ, Yoshimori T. The mechanisms and roles of selective autophagy in mammals. Nat Rev Mol Cell Biol. 2023;24:167–85.

Article  CAS  PubMed  Google Scholar 

Yun CW, Kim HJ, Lim JH, Lee SH. Heat shock proteins: agents of cancer development and therapeutic targets in anti-cancer therapy. Cells. 2019;9:60.

Article  PubMed  PubMed Central  Google Scholar 

Rosenzweig R, Nillegoda NB, Mayer MP, Bukau B. The Hsp70 chaperone network. Nat Rev Mol Cell Biol. 2019;20:665–80.

Article  CAS  PubMed  Google Scholar 

Velasco L, Dublang L, Moro F, Muga A. The complex phosphorylation patterns that regulate the activity of Hsp70 and its cochaperones. Int J Mol Sci. 2019;20:4122.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reynhout S, Janssens V. Physiologic functions of PP2A: lessons from genetically modified mice. Biochim Biophys Acta Mol Cell Res. 2019;1866:31–50.

Article  CAS  PubMed  Google Scholar 

Duong FH, Dill MT, Matter MS, Makowska Z, Calabrese D, Dietsche T, Ketterer S, Terracciano L, Heim MH. Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53. Carcinogenesis. 2014;35:114–22.

Article  CAS  PubMed  Google Scholar 

Gong S-J, Feng X-J, Song W-H, Chen J-M, Wang S-M, Xing D-J, Zhu M-H, Zhang S-H, Xu A-M. Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma. Cancer Biol Ther. 2016;17:151–62.

Article  CAS  PubMed  Google Scholar 

Yu S, Li L, Wu Q, Dou N, Li Y, Gao Y. PPP2R2D, a regulatory subunit of protein phosphatase 2A, promotes gastric cancer growth and metastasis via mechanistic target of rapamycin activation. Int J Oncol. 2018;52:2011–20.

CAS  PubMed  Google Scholar 

Sablina AA, Hector M, Colpaert N, Hahn WC. Identification of PP2A complexes and pathways involved in cell transformation. Can Res. 2010;70:10474–84.

Article  CAS  Google Scholar 

He J-J, Shang L, Yu Q-W, Jiao N, Qiu S, Zhu W-X, Wu D-F, Tian Y-E, Zhang Q. High expression of protein phosphatase 2 regulatory subunit B’’alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation. World J Gastrointest Oncol. 2021;13:716.

Article  PubMed  PubMed Central  Google Scholar 

Chen H, Xu J, Wang P, Shu Q, Huang L, Guo J, Zhang X, Zhang H, Wang Y, Shen Z, et al. Protein phosphatase 2 regulatory subunit B’’Alpha silencing inhibits tumor cell proliferation in liver cancer. Cancer Med. 2019;8:7741–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng X, He X, Yang Z, Huang J, Zhao L, Wen M, Hu X, Zou Z. Clustering analysis and prognostic model based on PI3K/AKT-related genes in pancreatic cancer. Front Oncol. 2023;13:1112104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang JY, Huo YM, Yang MW, Shen Y, Liu DJ, Fu XL, Tao LY, He RZ, Zhang JF, Hua R. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A–c-Myc axis. Mol Oncol. 2021;15:3076–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, Johnson F, Kovach JS. Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase I TrialPhase I trial of LB-100, an inhibitor of PP2A. Clin Cancer Res. 2017;23:3277–84.

Article  CAS  PubMed  Google Scholar 

Yue J, Vendramin R, Liu F, Lopez O, Valencia MG, Gomes Dos Santos H, Gaidosh G, Beckedorff F, Blumenthal E, Speroni L, et al. Targeted chemotherapy overcomes drug resistance in melanoma. Genes Dev. 2020;34:637–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen A, Dzulko M, Murr J, Yen Y, Schneider G, Krämer OH. Class 1 histone deacetylases and ataxia-telangiectasia mutated kinase control the survival of murine pancreatic cancer cells upon dNTP depletion. Cells. 2021;10:2520.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L, Wirth M, et al. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut. 2020;69:1472–82.

Article  PubMed  Google Scholar 

Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, Konukiewitz B, Ollinger R, Zwiebel M, Strong A, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018;554:62–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dejung M, Subota I, Bucerius F, Dindar G, Freiwald A, Engstler M, Boshart M, Butter F, Janzen CJ. Quantitative proteomics uncovers novel factors involved in developmental differentiation of Trypanosoma brucei. PLoS Pathog. 2016;12:e1005439.

Article  PubMed  PubMed Central  Google Scholar 

Kiweler N, Brill B, Wirth M, Breuksch I, Laguna T, Dietrich C, Strand S, Schneider G, Groner B, Butter F, et al. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells. Arch Toxicol. 2018;92:2227–43.

Article  CAS  PubMed  Google Scholar 

Perez-Riverol Y, Bai J, Bandla C, Garcia-Seisdedos D, Hewapathirana S, Kamatchinathan S, Kundu DJ, Prakash A, Frericks-Zipper A, Eisenacher M, et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50:D543–52.

Artic